MPO/Myeloperoxidase Antibody (18B7): sc-66106
- MPO/Myeloperoxidase Antibody (18B7) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against purified MPO of human origin
- recommended for detection of MPO of human origin by WB and IP
- See MPO light chain/Myeloperoxidase (A-5): sc-365436 for MPO/Myeloperoxidase antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for MPO/Myeloperoxidase Antibody (18B7). This work is in progress.
QUICK LINKS
MPO Antibody (18B7) is a mouse monoclonal IgG1 antibody that detects myeloperoxidase (MPO) in human samples through western blotting (WB) and immunoprecipitation (IP) applications. Anti-MPO antibody (18B7) plays a crucial role in understanding the function of MPO, a heme protein that is essential for the immune response, particularly in neutrophils and polymorphonuclear leukocytes. MPO (18B7) antibody helps researchers study MPO′s role in generating hypochlorous acid and other reactive oxygen species, which are vital for the destruction of pathogens during the immune response. The proper functioning of MPO is critical, as deficiencies or dysfunctions in this enzyme can lead to increased susceptibility to infections and inflammatory diseases. Additionally, MPO is synthesized during the promyelocytic stage of myeloid differentiation and undergoes a series of post-translational modifications, including cotranslational N-linked glycosylation, which are essential for its maturation and activity. The glycosylation process not only aids in the proper folding and stability of MPO but also influences its interaction with other proteins, such as calreticulin, which assists in the transport of fully glycosylated MPO to the lysosomes. MPO monoclonal antibody (18B7) is therefore an invaluable tool for researchers studying the role of MPO in immune responses and its implications in various diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MPO/Myeloperoxidase Antibody (18B7) References:
- MPO (Myeloperoxidase) Reduces Endothelial Glycocalyx Thickness Dependent on Its Cationic Charge. | Manchanda, K., et al. 2018. Arterioscler Thromb Vasc Biol. 38: 1859-1867. PMID: 29903730
- Impact of MPO-ANCA-mediated oxidative imbalance on renal vasculitis. | Hilhorst, M., et al. 2018. Am J Physiol Renal Physiol. 315: F1769-F1776. PMID: 30207165
- A challenging diagnosis of MPO-C-ANCA EGPA. | Lim, G., et al. 2019. BMJ Case Rep. 12: PMID: 31296634
- MPO/HOCl Facilitates Apoptosis and Ferroptosis in the SOD1G93A Motor Neuron of Amyotrophic Lateral Sclerosis. | Peng, J., et al. 2022. Oxid Med Cell Longev. 2022: 8217663. PMID: 35178161
- Dual-Positive MPO- and PR3-ANCA-Associated Vasculitis Following SARS-CoV-2 mRNA Booster Vaccination: A Case Report and Systematic Review. | Baier, E., et al. 2022. Vaccines (Basel). 10: PMID: 35632410
- Clinical Significance of MPO-ANCA in Eosinophilic Granulomatosis With Polyangiitis: Experience From a Longitudinal Chinese Cohort. | Liu, S., et al. 2022. Front Immunol. 13: 885198. PMID: 35833130
- PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease. | Chen, DP., et al. 2023. JCI Insight. 8: PMID: 36626226
- MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer. | Kaira, K., et al. 2024. J Chemother. 36: 82-83. PMID: 37183486
- Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis. | Watanabe, K., et al. 2024. Intern Med.. PMID: 39019601
- Two cases of MPO-ANCA-positive hypertrophic pachymeningitis mimicking as intracranial infection. | Wang, J., et al. 2024. BMC Neurol. 24: 283. PMID: 39138403
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MPO/Myeloperoxidase Antibody (18B7) | sc-66106 | 100 µg/ml | $322.00 |